Effects of a Dipeptidyl Peptidase-4 Inhibitor Sitagliptininsulin on the Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes

Atherosclerosis Type 2 Diabetes Mellitus Dipeptidyl Peptidase-4 Inhibitor GLP-1 Clinical Trial

Official title: Chinese PLA General Hospital Hainan Branch

Status Not yet recruiting

Clinical Trial Summary

This study was to investigate the Effect of Sitagliptin, a dipeptidyl peptidase-4 inhibitor, on progression of coronary atherosclerosis in patients with type 2 diabetes.

Clinical Trial Description

This study was to investigate the Effect of Sitagliptin, a dipeptidyl peptidase-4 inhibitor, on progression of coronary atherosclerosis in patients with type 2 diabetes. ;

Related Conditions & MeSH terms

• Atherosclerosis
• Atherosclerosis Type 2 Diabetes Mellitus Dipeptidyl Peptidase-4 Inhibitor GLP-1
• Diabetes Mellitus
• Diabetes Mellitus, Type 2

• NCT number: NCT03602638
• Study type: Interventional
• Source: Chinese PLA General Hospital
• Contact: LI BO, MD
• Phone: +86089837330575
• Email: 22401919@qq.com
• Status: Not yet recruiting
• Phase: Phase 4
• Start date: October 1, 2018
• Completion date: December 1, 2020